Vishal Gulati

At Sensible Biotechnologies, we are building best-in-class platform for manufacturing of high-quality mRNA in a scalable way to unlock the next generation of mRNA medicines and strengthen the global biosecurity.

Accelerating molecular discovery through the power of Chemputation.

Lindus is an Accountable Research Organization, engineered to give biotech and pharmaceutical sponsors confidence and control to generate clinical data on time and on budget. In the last 3 years, Lindus has executed over 45 full-scope trials across cardiometabolic, respiratory, psychiatry, dermatology, womens health, and diagnostics. Behind each study is an integrated model spanning feasibility, central enrollment infrastructure, and flexible site models. Trials run on Citrus™, an AI-native trial operating system, and are governed by performance-based contracts with milestone-based payments. 82% of Lindus executed trials completed enrollment on or ahead of our proposed timeline. The company is backed by Dr. Bob Langer, Peter Thiel, and Dr. Tim Garnett.

We are an end-to-end biotech developing transformational medicines, with technology at our core. Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of lifes most devastating diseases. We leverage single-cell and multi-omics measurements directly from patient tissue, functional assays and machine learning to drive disease understanding — from cause to cure. Medicines born from high-resolution biology, machine learning and clinical insights. Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select druggable targets and develop transformational medicines.

Truly meaningful medicine comes from breakthroughsin deeply understanding patient biology. We are building the world’s leading predictive simulation of patient biology. We will empower the biopharma industry by informing the right experiments that identify and validate disease driving hidden effects.

Pelago is the world’s leading virtual clinic for substance use management. We are transforming substance use support—from prevention to treatment—delivering education, management skills, and opportunities for positive change to members struggling with substance use, most commonly tobacco, alcohol, opioids, and cannabis. Our solution gives employers the means to offer on-demand, personalized support to workers seeking to live healthier lives. Pelago’s cognitive behavioral therapy (CBT) and medication-assisted treatment (MAT) programs deliver convenient, accessible, and effective support that seamlessly integrates with health plans, pharmacy benefit managers, and wellness platforms. Visit www.pelagohealth.com for more information.

We need to shift to a world where we treat the individual, not just the disease. Our inventions work in combination with medicine to deliver personalized, optimized dosing, to provide bespoke universal healthcare access and improve outcomes for patients with chronic diseases. Closed Loop Medicine is a TechBio company developing combination prescription drug + software products, with the aim of bringing forward the promise of precision care. Our proprietary technology platform facilitates personalized drug dose optimization through integration of medicines and software with patient-led digital experiences and closed loop models of care. To learn more about our mission to deliver #PrecisionCareForAll, please visit: www.closedloopmedicine.com

Arctoris is a tech-enabled Partnership Research Organization (PRO) headquartered in Oxford. We combine our unique automation platform, Ulysses, with a world-class team of excellent laboratory scientists to guide and rapidly progress our partners’ drug discovery programs from target to candidate. Data is the lifeblood of research, and “Better Data leads to Better Decisions”. Our excellent service is built on: 1) Data quality: generating large reproducible datasets by leveraging robotics and wet lab automation, in turn empowering improved decision-making. 2) Our world-class team of experienced scientists: a true partner for your discovery work, consulting and advising on assay cascades and the path from target all the way to the clinic. 3) An "ecosystem of excellence”: we are a full-suite discovery PRO with partners in all adjacent disciplines, which allows us to stay agile and truly client-focused.

ZOE combines scientific research with cutting-edge AI to improve the health of millions. We are a remote-first, well-funded scale-up created by the world’s top scientists and backed by founders, investors, and entrepreneurs who have built multi-billion dollar tech companies. Our personalised nutrition program radically reimagines a fundamental human need – eating well for your body. Currently available in the US and the UK, ZOE is already helping tens of thousands of its members adopt a healthier lifestyle. Our collective work and expertise in biology, engineering, data science, and nutrition science have led to multiple breakthrough papers in leading scientific journals such as Nature Medicine, Science, The Lancet, and more. We value inclusivity, transparency, ownership, open-mindedness and diversity. We are passionate about delivering great results and learning in the open. We want our teams to have the freedom to make long-term, high-impact decisions, and the well-being of our teammates and the people around us is a top priority.

Our mission is to help breast cancer patients live longer, better lives through earlier detection. We combine new deep learning methods, data science and radiology insights to help doctors find malignancies in mammograms. According to external clinical trial results, Kheiron’s deep learning technology achieves state-of-the-art malignancy detection support in breast cancer screening. European regulatory approval is expected shortly.

Continua Kids: A neurotherapy center for uniquely abled kids, featuring expert Paediatric Neurologists and Developmental Behavioural Paediatricians specializing in autism diagnosis. Our comprehensive services include occupational, speech, ABA therapy, physiotherapy, and special education to support the well-being and development of every child. -OUR OBJECTIVE- We are creating a valuable secure data repository of elements, and journeys that will help build AI models to aid humanity solve major medical challenges.

Repositive is committed to accelerating the development of precision cancer therapies to the clinic by working with biopharmas and Contract Research Organisations (CROs) to improve the predictivity of pre-clinical cancer research. Through its Cancer Models Scout service, Repositive is helping biopharmas to optimise their pre-clinical cancer projects by identifying the most suitable cancer models for their requirements from its world-leading database of over 8000 models, as well as via outreach to an extended network of CRO contacts. Repositive works to connect researchers with the right CRO partners who have first-class expertise and years of experience in running similar studies, to ensure biopharmas receive the best advice for planning and conducting their oncology projects. Download our latest eBook on AI in drug discovery here: https://mailchi.mp/repositive.io/c1tpoe6oke

The world’s first Point-of-Care Highly Multiplex PCR MiniLab Platform empowers clinicians with 24/7 access to fast comprehensive actionable laboratory-quality molecular diagnostic results for the simultaneous in vitro diagnostic detection a range of targets reducing test result waiting times to about an hour. It is well documented that a fast accurate diagnosis and targeted treatment improves clinical outcomes while reducing costs and supports good antimicrobial stewardship. The MiniLab is designed to support the clinical sample collection workflow by minimizing pipetting steps as well allowing the lab to “push” its services out to decentralized labs. Built in QC features allow the lab to control the use of the platform and data integration allows the transfer of results. The easy-to-use sample-to-results MiniLab features a fully integrated Control Module that commands up to six fully automated Processing Modules making the MiniLab’s architecture scalable. The Processing Modules can run different panels with independent random access.

At Sensible Biotechnologies, we are building best-in-class platform for manufacturing of high-quality mRNA in a scalable way to unlock the next generation of mRNA medicines and strengthen the global biosecurity.

Cambridge Enterprise is the commercialisation arm of the University of Cambridge. At Cambridge Enterprise, we help University of Cambridge members create beneficial impact from their research and expertise that can change the world, through academic consultancy, intellectual property management, development and licensing, venture building, venture funding and convening and connecting the wider Cambridge innovation ecosystem. Our success is measured in the success of our University partners as they bring their work to market, be it ground-breaking stem cell research, critical suspension technology used in Formula 1 racing, or a flower seed mix to enable bees to flourish and crops grow. We’re here to make the world a better place by helping to create a legacy of products, services and advice that benefit not just the University and the UK, but everyone.

Accelerating molecular discovery through the power of Chemputation.

Lindus is an Accountable Research Organization, engineered to give biotech and pharmaceutical sponsors confidence and control to generate clinical data on time and on budget. In the last 3 years, Lindus has executed over 45 full-scope trials across cardiometabolic, respiratory, psychiatry, dermatology, womens health, and diagnostics. Behind each study is an integrated model spanning feasibility, central enrollment infrastructure, and flexible site models. Trials run on Citrus™, an AI-native trial operating system, and are governed by performance-based contracts with milestone-based payments. 82% of Lindus executed trials completed enrollment on or ahead of our proposed timeline. The company is backed by Dr. Bob Langer, Peter Thiel, and Dr. Tim Garnett.